PATENT CLAIM ANALYSIS

Application Number: 15755801
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-03
Patent Classification: ["514", "253070"]

Abstract:
The present invention belongs to the field of pharmaceutical formulation, and particularly relates to an aripiprazole injectable suspension formulation having prolonged shelf life, and methods of using the formulation in treating schizophrenia and related diseases. In another aspect, the present invention also relates to a method of prolonging shelf life of an aripiprazole injectable suspension formulation.

Claim (Index 18):
The method of  claim 17 , wherein the ratio (by weight) of the cellulose-based suspending agent to the polyoxyethylene (20) sorbitan monooleate is 1:0.5 to 1:6, preferably 1:0.5 to 1:3, and more preferably 1:0.5, 1:1, 1:2 or 1:3.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.64865
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13338827', '10968482', '11979145', '14129713', '14507303']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.778029986907478
- 35 USC 102 Novelty (BERT): 0.5067813761842112
- Combined Prediction Score: 0.7509051258351513
- Mean Citation Score: 249.497078
- Max Citation Score: 259.14893
- Similarity Product: 180.2172322685552

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test